147 related articles for article (PubMed ID: 32767666)
1. Palmar-plantar erythrodysesthesia associated with high-dose methotrexate: Case report.
Chauhan P; Gupta A; Kumar S; Bishnu A; Nityanand S
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1270. PubMed ID: 32767666
[TBL] [Abstract][Full Text] [Related]
2. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.
Karol SE; Yang W; Smith C; Cheng C; Stewart CF; Baker SD; Sandlund JT; Rubnitz JE; Bishop MW; Pappo AS; Jeha S; Pui CH; Relling MV
Cancer; 2017 Sep; 123(18):3602-3608. PubMed ID: 28493546
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel induced severe palmar plantar erythrodysesthesia.
Kharmoum S; Errihani H
Pan Afr Med J; 2018; 30():70. PubMed ID: 30344854
[No Abstract] [Full Text] [Related]
4. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
Harris CS; Wang D; Carulli A
J Oncol Pharm Pract; 2014 Feb; 20(1):73-80. PubMed ID: 23478198
[TBL] [Abstract][Full Text] [Related]
5. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
[TBL] [Abstract][Full Text] [Related]
6. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
7. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
[TBL] [Abstract][Full Text] [Related]
9. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
10. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
Ni C; Fang J; Qian H; Xu Q; Shen F
J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
[TBL] [Abstract][Full Text] [Related]
11. Severe palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabine.
Alzghari SK; Seago SE; Cable CT; Herrington JD
J Oncol Pharm Pract; 2017 Sep; 23(6):476-480. PubMed ID: 27530244
[TBL] [Abstract][Full Text] [Related]
12. Influence of mechanical stress on palmoplantar erythrodysesthesia--a case report.
Jung S; Sehouli J; Patzelt A; Lademann J
Oncol Res Treat; 2015; 38(1-2):42-4. PubMed ID: 25765506
[TBL] [Abstract][Full Text] [Related]
13. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Meadows KL; Rushing C; Honeycutt W; Latta K; Howard L; Arrowood CA; Niedzwiecki D; Hurwitz HI
Support Care Cancer; 2015 May; 23(5):1311-9. PubMed ID: 25341548
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate-induced reversible grade 4 hyperbilirubinaemia and transaminitis in an adolescent with Burkitt Leukaemia.
Khera S; Ranjan R; Ramachandran S; Beriwal A
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33414115
[TBL] [Abstract][Full Text] [Related]
15. An exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE).
Law A; Dyson S; Anthony D
J Adv Nurs; 2015 Aug; 71(8):1825-32. PubMed ID: 25702709
[TBL] [Abstract][Full Text] [Related]
16. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.
Farr KP; Safwat A
Case Rep Oncol; 2011 Apr; 4(1):229-35. PubMed ID: 21537373
[TBL] [Abstract][Full Text] [Related]
17. Anticancer drug induced palmar plantar erythrodysesthesia.
Palaniappan M; Srinivasamurthy S; Dubashi B; Chandrasekaran A
J Clin Diagn Res; 2014 Oct; 8(10):HC01-3. PubMed ID: 25478366
[TBL] [Abstract][Full Text] [Related]
18. Palmar-plantar erythrodysesthesia.
Gupta A; Mehta A; Khanna S
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359464
[No Abstract] [Full Text] [Related]
19. Paclitaxel-Induced Palmar-Plantar Erythrodysesthesia.
Wahab A; Khakwani M; Ehsan H; Bellam N
Cureus; 2020 Nov; 12(11):e11507. PubMed ID: 33214972
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity with leukoencephalopathy after a single intravenous high dose of methotrexate in a patient with lymphoma.
Cohen Y; Lossos A; Polliack A
Acta Haematol; 2002; 107(3):185-6. PubMed ID: 11978942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
